Dr Karin Straathof
@karinstraathof.bsky.social
Associate Professor in Tumour Immunology - UCL Cancer Institute @uclcancer
Honorary Consultant Paediatric Oncology - Great Ormond Street Hospital
Development and clinical translation of engineered T cells for #childhood cancer
@cancergrand NexTGen
Honorary Consultant Paediatric Oncology - Great Ormond Street Hospital
Development and clinical translation of engineered T cells for #childhood cancer
@cancergrand NexTGen
This is encouraging: a glimps of what can be achieved with CAR T cells for childhood solid tumours. Spurs on research into refining CAR T cells so they achieve lasting remissions for patients with neuroblastoma, DMG and other #childhoodcancers for which current treatments are not providing a cure.
A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free for over 18 years thanks to CAR T-cell therapy
CAR T-cells enable record-breaking 18-year nerve cancer remission
A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free for over 18 years thanks to CAR T-cell therapy
www.newscientist.com
February 17, 2025 at 10:10 PM
This is encouraging: a glimps of what can be achieved with CAR T cells for childhood solid tumours. Spurs on research into refining CAR T cells so they achieve lasting remissions for patients with neuroblastoma, DMG and other #childhoodcancers for which current treatments are not providing a cure.
An encouraging glimps of what can be achieved with CAR T cells for childhood solid tumours. Spurs on our research into refining CAR T cells so they achieve lasting remissions for patients with neuroblastoma, DMG and other #childhoodcancers for which current treatments are not providing a cure.
Woman who had pioneering cancer treatment 18 years ago still in remission
Woman who had pioneering cancer treatment 18 years ago still in remission
Researchers say woman treated for neuroblastoma as a child is longest known survivor after having CAR T-cell therapy
A woman treated with a pioneering type of immunotherapy for a solid tumour has been in remission for more than 18 years with no further…
www.theguardian.com
February 17, 2025 at 10:03 PM
An encouraging glimps of what can be achieved with CAR T cells for childhood solid tumours. Spurs on our research into refining CAR T cells so they achieve lasting remissions for patients with neuroblastoma, DMG and other #childhoodcancers for which current treatments are not providing a cure.
Reposted by Dr Karin Straathof
Annual reminder that #duvetknowitschristmas is the hashtag to follow this evening.
December 24, 2024 at 8:11 PM
Annual reminder that #duvetknowitschristmas is the hashtag to follow this evening.
Reposted by Dr Karin Straathof
Applications are now open for The Little Princess Trust’s 2025 New Ideas Grants!
We are keen to back innovation in children’s cancer research, supporting promising ideas which may be challenging to find funding for from traditional funders.
To apply, see www.cclg.org.uk/research/ccl....
We are keen to back innovation in children’s cancer research, supporting promising ideas which may be challenging to find funding for from traditional funders.
To apply, see www.cclg.org.uk/research/ccl....
December 12, 2024 at 4:19 PM
Applications are now open for The Little Princess Trust’s 2025 New Ideas Grants!
We are keen to back innovation in children’s cancer research, supporting promising ideas which may be challenging to find funding for from traditional funders.
To apply, see www.cclg.org.uk/research/ccl....
We are keen to back innovation in children’s cancer research, supporting promising ideas which may be challenging to find funding for from traditional funders.
To apply, see www.cclg.org.uk/research/ccl....
Reposted by Dr Karin Straathof
Amazing work from UCL colleagues @ojlucas.bsky.social and @zaccasimo.bsky.social pairing proliferation rates with evolutionary dynamics from scDNA-seq data 🤩
🚨So proud to present the first study from our @ccg-ucl.bsky.social group together with @charlesswanton.bsky.social @NnennayaKanu and led by @ojlucas.bsky.social with key collaboration @sophie-ward.bsky.social and fundamental support @rijazaidi.bsky.social @abibunkum.bsky.social & others
Out now👇
🧵👇
Out now👇
🧵👇
Characterizing the evolutionary dynamics of cancer proliferation in single-cell clones with SPRINTER - Nature Genetics
Single-cell Proliferation Rate Inference in Non-homogeneous Tumors through Evolutionary Routes (SPRINTER) allows users to infer proliferation rates of individual clones within a tumor from single-cell...
doi.org
November 29, 2024 at 5:41 PM
Amazing work from UCL colleagues @ojlucas.bsky.social and @zaccasimo.bsky.social pairing proliferation rates with evolutionary dynamics from scDNA-seq data 🤩
Reposted by Dr Karin Straathof
🌟 Registration is OPEN for the CCLG + TYAC Annual Conference 2025, a must-attend event for #clinical, #healthcare, and #research professionals working in children and young people's cancer.
⏰ Early bird discount for members ends 16 Jan 2025!
View the programme & register bit.ly/3H6gaTu
#CCLG2025
⏰ Early bird discount for members ends 16 Jan 2025!
View the programme & register bit.ly/3H6gaTu
#CCLG2025
November 26, 2024 at 4:02 PM
🌟 Registration is OPEN for the CCLG + TYAC Annual Conference 2025, a must-attend event for #clinical, #healthcare, and #research professionals working in children and young people's cancer.
⏰ Early bird discount for members ends 16 Jan 2025!
View the programme & register bit.ly/3H6gaTu
#CCLG2025
⏰ Early bird discount for members ends 16 Jan 2025!
View the programme & register bit.ly/3H6gaTu
#CCLG2025
Reposted by Dr Karin Straathof
A new CAR-T cell therapy has delivered promising results in treating patients with an aggressive blood cancer, in findings from a clinical trial led by Prof Martin Pule and Dr Claire Roddie from UCL Cancer Institute and @uclh.bsky.social
www.ucl.ac.uk/news/2024/no...
www.ucl.ac.uk/news/2024/no...
New CAR-T cell therapy gives hope for patients with aggressive blood cancer
A new chimeric antigen receptor T cell (CAR-T) therapy has delivered promising results in treating patients with an aggressive blood cancer, in results from a clinical trial led by researchers at UCL ...
www.ucl.ac.uk
November 29, 2024 at 2:09 PM
A new CAR-T cell therapy has delivered promising results in treating patients with an aggressive blood cancer, in findings from a clinical trial led by Prof Martin Pule and Dr Claire Roddie from UCL Cancer Institute and @uclh.bsky.social
www.ucl.ac.uk/news/2024/no...
www.ucl.ac.uk/news/2024/no...